Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Core Viewpoint - Artelo Biosciences, Inc. has successfully closed a public offering of common stock and pre-funded warrants, raising approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on lipid-signaling pathways for various medical conditions [1][2]. Group 1: Offering Details - The company offered 640,924 shares of common stock at a public price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The gross proceeds from the offering were approximately $3.0 million before deducting underwriting discounts and other expenses [2]. - Underwriters were granted a 45-day option to purchase an additional 102,272 shares at the public offering price to cover over-allotments [2]. Group 2: Regulatory and Documentation - The shares and warrants were offered under a "shelf" registration statement on Form S-3, which was filed with the SEC on July 6, 2023, and declared effective on July 14, 2023 [3]. - The final prospectus supplement and accompanying base prospectus were filed with the SEC on September 5, 2025, and are available on the SEC's website [4]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing significant unmet needs in various medical conditions including cancer and pain [7]. - The company has adopted a corporate finance initiative to deploy excess capital into digital assets as part of its treasury strategy [7].